[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570273":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":24,"responsibleParty":34,"collaborators":24,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":24,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":24,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":64,"whyStopped":24,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":24},{"fullName":5,"class":6},"Liaquat National Hospital & Medical College","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Gabapentin Group (Group G): Participants receiving Gabapentin 300 mg as a pre-treatment.","EXPERIMENTAL",[12],"Drug: Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin",{"label":14,"type":15,"description":14,"interventionNames":16},"Placebo Group (Group P): Participants receiving a placebo as a pre-treatment.","PLACEBO_COMPARATOR",[17],"Other: Placebo Oral Tablet",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin","In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Placebo Oral Tablet","The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.",[14],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":24},"AEMAN ZUBAIR Dr, FCPS I","CONTACT","+923332325316",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","SYEDA AEMAN ZUBAIR","DR","100570273","phase-1-gabapentin-and-pressor-response-to-intubation-100570273",false,"NCT06705101","Gabapentin and Pressor Response to Intubation","GABAPENTIN ATTENUATES THE PRESSOR RESPONSE TO DIRECT LARYNGOSCOPY AND TRACHEAL INTUBATION","Inclusion Criteria:\n\n* ASA I or II patients (American Society of Anesthesiologists Physical Status Classification).\n* Age between 18 and 59 years.\n* Scheduled for elective surgery under general anesthesia with endotracheal intubation.\n\nExclusion Criteria:\n\n* Anticipated difficult intubation.\n* ASA III or greater.\n* Patients with hiatus hernia or gastro-esophageal reflux disease (GERD).\n* Body weight more than 20% of ideal body weight.\n* Patients on antihypertensive drugs, sedatives, hypnotics, or antidepressants.","ALL","18 Years","59 Years",{"count":49,"type":50},144,"ESTIMATED","INTERVENTIONAL",[53,54],"PHASE1","PHASE2","This study evaluates the effectiveness of oral gabapentin in reducing the pressor response (increased MAP, HR, and BP) during laryngoscopic intubation. It is a prospective, double-blind randomized controlled trial involving 144 patients undergoing elective surgery. Gabapentin 300 mg or placebo will be administered preoperatively, with hemodynamic parameters monitored before and after intubation. The study aims to determine if gabapentin attenuates the sympathetic stress response compared to placebo.",[57,58],"Elective Surgical Patients","Blood Pressure",[60,61,62,63],"Gabapentin","Laryngoscopy","Hemodynamic Stability","Pressor Response","NOT_YET_RECRUITING","2024-11-22",{"date":67,"type":68},"2024-11-26","ACTUAL",{"date":70,"type":50},"2024-12-15",{"date":72,"type":50},"2025-07-16",{"name":5,"class":6}]